NCT01639911View on ClinicalTrials.gov

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 14, 2013

Primary Completion Date

July 28, 2016

Study Completion Date

July 28, 2016

Conditions
Malignant Neoplasm of BreastCNS MalignancyMalignant Neoplasm of Gastrointestinal TractGenitourinary Neoplasms Malignancy and Gender UnspecifiedHead and Neck NeoplasmsMelanomaMalignant Neoplasm of Thorax
Interventions
DRUG

Alisertib

Alisertib at the assigned dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle.

DRUG

Pazopanib

Pazopanib at the assigned dose once a day continuously for the duration of treatment.

Trial Locations (1)

60612

University of Illinois Cancer Center, Chicago

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

University of Illinois at Chicago

OTHER